At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 53 enrolled
Drug / intervention
strain CVD 1208S-122 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of the Safety, Tolerability, and Immunogenicity of Oral Doses of CVD 1208S-122, a Prototype Attenuated Shigella Flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia Coli Antigens
In Brief
A Phase 1 clinical trial evaluating strain CVD 1208S-122 and Placebo for Shigella Infection and Enterotoxigenic Escherichia Coli Infection. Completed, enrolled 53 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartSep 2022
Primary CompletionOct 2024
TodayJul 2026
First PostedNov 18, 2020
Enrollment StartSep 29, 2022
Primary CompletionOct 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.6 years ago
Interventions
strain CVD 1208S-122biological
Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
Placeboother
Sodium bicarbonate buffer